/Investor DB

Intermediate Capital Group

Private equity

London · Growth–Late Stage · 16 people tracked

Also known as ICG ALTERNATIVE INVESTMENT LIMITED · ICG EUROPE S.A.R.L. · Icg Investments Inc · ICG MANAGER LIMITED

Find your way into Intermediate Capital Group

Each arrow is one introduction. Sign up to fill in the first one.

2,710 people can intro you to David

Ask Udhay Furtado to introduce you to David Bicarregui

You →Udhay · together at Dulwich College →David

331 people can intro you to Antje

Ask Jamie Chen to introduce you to Antje Hensel-Roth

You →Jamie · together at Russell Reynolds Associates →Antje

200 people can intro you to William

Ask Sam Okafor to introduce you to William Rucker

You →Sam · together at UK Dementia Research Institute →William

Sign up to find every way you can get introduced to Intermediate Capital Group

  • Your email: who you already know at Intermediate Capital Group, and who your contacts know
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Intermediate Capital Group team
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

✨ Fox Verdict
Sign up to see your fit

Investment thesis

ICG operates as a global alternative asset manager offering flexible and responsible capital solutions across a broad platform that includes structured capital, private equity secondaries, strategic equity, private debt, credit (asset-backed finance, syndicated loans, multi-asset credit), and real assets (infrastructure and real estate). The firm originates differentiated opportunities across sectors and geographies, invests responsibly, and aims to deliver long-term value for clients, institutional investors, and shareholders. With operations spanning Europe, Asia Pacific, North America, and the Middle East, ICG emphasizes local knowledge, specialist experience, and sustainable business growth.

Source: firm website, verified Sep 29, 2026.

Stage
Growth–Late Stage
Check
$5M – $50M
HQ
London, GB
Instruments
Equity · Debt
Founded
1989
AUM
$49.7B
Tracked investments
6
IPOs
1

Team · 16 people

from the firm's website & public directories
Alan Isenberg· Global Head of the Client Solutions Groupin

Leads ICG's Client Solutions Group, based in New York.

Andrew Sykes· Senior Independent Director

Senior Independent Director and Board member, serving on several committees.

Andy Lewis· Global Head of Legal

Global Head of Legal within ICG's Corporate Business Services.

Maisie Le Masurier· Corporate Communications

Corporate Communications contact within ICG's media relations team.

Matthew Lester· Independent Non-Executive Director

Independent non-executive director who chairs the Audit Committee and serves on other committees.

Sonia Baxendale· Independent Non-Executive Director

Independent non-executive director who chairs the Risk Committee and sits on the Audit Committee.

Wooseok Jun· Head of Asia-Pacific Corporate

What they invest in

from 5 of 6 portfolio companies

Biotech ×3Advanced Manufacturing ×2Healthtech ×2FoodTech ×1Hardware ×1Medical Devices ×1

HQs:United States×3Netherlands×1

Investments · 6 tracked

founders shown can be your intro path

By year:2025 · 12023 · 12021 · 13 dated

Eliem TherapeuticsNASDAQ: CLYMMay 2021

Eliem Therapeutics is a clinical-stage biotechnology company developing monoclonal antibodies targeting immune-mediated diseases, with budoprutug, an anti-CD19 antibody designed to deplete B cells in conditions including primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, and CLYM116, an anti-APRIL antibody for IgA nephropathy and related B-cell mediated diseases.

BiotechWilmington, US

Valerie Morisset(Executive Officer)inErin Lavelle(Executive Officer)inRobert Azelby(Executive Officer, Director)James Bucher(Executive Officer)Leone Patterson(Director)

BoardAdam Rosenberg(Director)

Co-investorsManta Ray VenturesAccess BiotechnologyACORN BIOVENTURESLifeArc VenturesRA Capital

CuraSen Therapeuticscurasen.comin✓ verified

CuraSen Therapeutics is a privately funded biopharmaceutical company developing treatments that selectively activate adrenergic receptors in the brain to restore noradrenergic signaling.

BiotechHealthtechSan Carlos, US

Anthony Ford(Executive Officer, Director)inBenjamin Potter(Executive Officer)Henry Skinner(Director)Liam Ratcliffe(Director)in

BoardRon Hunt(Director)inLoretta Tse, Ph.D.(Director)

Co-investorsAlta PartnersLongitude Capitalabrdn plcJohnson & Johnson Innovation – JJDCNew Leaf Venture PartnersPappas Capital+2 more

Amolyt Pharmaamolytpharma.comJan 2023 · $138M

Developing therapeutic peptides targeting rare endocrine diseases (past investment).

Co-investorsAndera PartnersATEM Capital FundCTI Life Sciences Fund L.P.EQT Life SciencesKurma PartnersLSP (Life Sciences Partners)+5 more

Kee Safetykeesafety.comin

Kee Safety designs, manufactures, and supplies fall protection and working-at-height safety systems, including guardrails, rigid rail systems, and related equipment, along with consulting and assessment services.

Advanced ManufacturingHardware

Co-investorsInflexion65 Equity Partners Pte. Ltd.Investcorp

Van Gelovenvangeloven.comin

Van Geloven is a Dutch snacks manufacturer with multiple brand portfolios including Mora, Van Dobben, and others, serving food service and retail channels.

Advanced ManufacturingFoodTech

Co-investorsTowerBrook

Wugenwugen.comAug 2025 · $115M

Allotera (formerly Wugen) develops allogeneic T-cell therapies.

BiotechHealthtechMedical DevicesSt. Louis, US

Ayman Kabakibi(Executive Officer)inCherry Thomas(Executive Officer)inKumar Srinivasan(Executive Officer, Director)inKeith Vendola(Executive Officer)Daniel M Kemp(Executive Officer, Director)Matthew Cooper(Executive Officer)

Co-investorsAisling CapitalAlpha Wave GlobalBioGenerator VenturesRiverVest Venture PartnersAbingworthFidelity Investments+1 more

Exits · 1

1 IPOs

Eliem TherapeuticsNASDAQ: CLYM

Portfolio news

latest coverage across their companies
Wugen Raises $115M in Funding

Wugen · finsmes.com · Aug 28, 2025

Fund performance · per public LP disclosures · 28

as of Sep 2025
FundVintageCommittedNet IRRTVPIDPI
ICG Europe Fund IX SCSpLPs: Connecticut Retirement Plans and Trust Funds, Pennsylvania Public School Employees' Retirement System2025——1.35x—
ICG Centre Street Partnership, L.P. - Series NLPs: New York City Board of Education Retirement System2024—8.8%1.06x0.15x
ICG Centre Street Partnership, L.P. - Series SLPs: New York City Board of Education Retirement System2024—6.2%1.05x0.26x
ICG Global Co-InvestmentLPs: Connecticut Retirement Plans and Trust Funds2024——1.00x—
ICG Global Loan FundLPs: Connecticut Retirement Plans and Trust Funds2024——1.10x—
ICG Global Total Credit FundLPs: Connecticut Retirement Plans and Trust Funds2024——1.10x—
ICG Strategic Equity Co-Investment Fund V-ALPs: New York City Employees' Retirement System, New York City Police Pension Fund, New York City Fire Department Pension Fund2024——1.66x1.66x
ICG Strategic Equity Fund V (USD)LPs: Teachers' Retirement System of the City of New York, California State Teachers' Retirement System, New York City Employees' Retirement System +3 more2024——1.48x0.00x
ICG Strategic Equity Fund V (USD) V-ALPs: New York City Fire Department Pension Fund2024——1.49x—
ICG Europe Mid-Market Fund II SCSpLPs: Pennsylvania Public School Employees' Retirement System, Connecticut Retirement Plans and Trust Funds2023——1.17x—
ICG North American Credit Partners III, L.P.LPs: Connecticut Retirement Plans and Trust Funds2023——1.00x0.10x
ICG Strategic Equity Fund VLPs: Teachers' Retirement System of the City of New York, New York City Police Pension Fund, Los Angeles City Employees' Retirement System +1 more2023——1.49x0.00x
ICG Europe Fund VIII SCSpLPs: New Jersey Division of Investment, Florida State Board of Administration, Connecticut Retirement Plans and Trust Funds2022—8.0%1.10x0.10x
ICG Europe Fund VIII Feeder SCSpLPs: Pennsylvania Public School Employees' Retirement System, Florida State Board of Administration, Robert Wood Johnson Foundation2021—22.9%1.41x0.15x
ICG Exelsior SCSpLPs: Empire State Development – New York Ventures2021——1.20x0.08x
ICG Strategic Equity Co-Investment Fund IVLPs: New York City Police Pension Fund2021—5.4%1.18x—
ICG Strategic Equity Fund IVLPs: California State Teachers' Retirement System, Teachers' Retirement System of the City of New York, New York City Police Pension Fund +2 more2021—14.5%1.35x0.28x
ICG Europe Mid-Market FundLPs: Pennsylvania Public School Employees' Retirement System2020—18.7%1.50x0.72x
ICG North American Private Debt Fund IILPs: Pennsylvania Public School Employees' Retirement System2019—10.0%1.20x0.83x
ICG Europe Fund VIILPs: Pennsylvania Public School Employees' Retirement System, Connecticut Retirement Plans and Trust Funds2018—14.3%1.60x0.73x
ICG Europe Fund VII Feeder SCSpLPs: Pennsylvania Public School Employees' Retirement System2018—14.6%1.64x1.24x
ICG Strategic Equity Fund III LPLPs: California State Teachers' Retirement System, Teachers' Retirement System of the City of New York, New York City Board of Education Retirement System2018—24.5%2.12x1.11x
ICG Europe Fund VI, L.P.LPs: Pennsylvania Public School Employees' Retirement System2015—19.5%1.82x1.75x
ICG Europe Fund V, L.P.LPs: Pennsylvania Public School Employees' Retirement System2011—7.9%1.29x1.24x
ICG CENTRE ST PARTNERSHIPLPs: New York City Board of Education Retirement System———1.14x—
ICG STRATEGIC EQUITY COINV IIILPs: New York City Board of Education Retirement System———2.34x—
ICG STRATEGIC EQUITY COINV IVLPs: New York City Board of Education Retirement System———1.11x—
ICG STRATEGIC EQUITY COINV VLPs: New York City Board of Education Retirement System———1.00x—

Source: public limited-partner disclosures (CalPERS, CalSTRS). Net IRR / TVPI / DPI as reported by the limited partner; a fund's early-year IRR is an interim estimate (J-curve).

Frequently asked questions

How many investments has Intermediate Capital Group made?
Intermediate Capital Group has 6 tracked investments, 1 of which have exited, including 1 dated in the last 24 months.
What stage does Intermediate Capital Group invest at?
Intermediate Capital Group invests at the Growth, Late Stage stages.
What is Intermediate Capital Group's typical check size?
Intermediate Capital Group typically writes checks of $5M – $50M.
What sectors does Intermediate Capital Group focus on?
Intermediate Capital Group focuses on Biotech, Climate Tech, Energy, PropTech, Sector Agnostic.
Where is Intermediate Capital Group located?
Intermediate Capital Group is headquartered in London, GB.

Media · Podcasts & interviews

from their channel

The role of private capital within diversified pension portfolios

ICG plc

ICG CIO & CEO Benoît Durteste: Delivering significant growth

ICG plc

Images

Intermediate Capital Group photoIntermediate Capital Group photoIntermediate Capital Group photoIntermediate Capital Group photoIntermediate Capital Group photoIntermediate Capital Group photo

Similar investors

Featured in lists